Read Larry Connors' blog – Short Term Trading Strategies
In a release, the Company noted that this high-throughput, automated platform enables researchers to find novel genetic variations associated with complex disease.
Affymetrix said that the Axiom Solution will support both whole-genome association and candidate gene association studies with a level of customization not currently available. Researchers will no longer be constrained by the content of fixed-panel arrays. The complete genotyping platform employs enzyme-mediated, single-base sequencing steps for specificity in conjunction with affordable, reproducible, and highly automated workflows.
The solution is configured to continually validate and incorporate the output of large-scale sequencing projects. Initial offerings are designed from public databases of human variations and cover historical HapMap data supplemented by subsequent releases of additional variants. In addition, Affymetrix is screening millions of putative SNPs and insertions/deletions that are being discovered by the 1000 Genomes Project and other sources, and will make these available to researchers using the Axiom Solution.
"Axiom technology has the capability to routinely screen, validate, and convert sequence variants into high-throughput assays," said Dr. Keith Jones, vice president of assay and application development at Affymetrix. "A major strength of this new solution is the assay that allows random access to the genome, coupled with the accuracy of a highly specific, ligation-based approach."
"The Axiom Solution is a revolution in customer choice and takes advantage of a technology model similar to the digital media industry," said Kevin King, president and CEO of Affymetrix. "Pre-selected, store-bought music and video content have given way to powerful online digital databases that offer customers maximum flexibility. Researchers can now create their own 'playlist' in the form of custom arrays that deliver maximum scientific value to their research."
Affymetrix added that it will also offer Axiom Genotyping Services through the Affymetrix Research Services Laboratory (ARSL), which has run more than 250,000 genotyping samples to date, including a large portion of the Wellcome Trust Case Control Consortium.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia.
((Comments on this story may be sent to health@closeupmedia.com))
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
